Drug updated on 5/17/2024
Dosage Form | Tablet (oral; 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, 20 mg) |
Drug Class | Sphingosine 1-phosphate receptor modulators |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
Latest News
![loading GIF](/img/news-loading.gif)
Summary
- Ponesimod (Ponvory) is indicated for the treatment of relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. It is recognized as a high-efficacy drug that likely results in a significant reduction of individuals with relapses at 24 months.
- Four systematic reviews/meta-analyses were analyzed to collate information on Ponvory's efficacy and safety profile in comparison to other Disease Modifying Therapies (DMTs).
- Compared to Natalizumab, Cladribine, Alemtuzumab, and Ublituximab, which are regarded as top-tier DMTs due to their higher effectiveness over two years against placebo, Ponesimod does not rank among these but still maintains a favorable position within the treatment landscape.
- In terms of safety profiles among high-efficacy DMTs: Alemtuzumab shows higher rates of adverse events, while Ponesimod exhibits no significant differences in terms of serious adverse events, suggesting it has a comparatively balanced risk-benefit ratio.
- The studies did not provide detailed insights into population types or subgroup specifics beyond mentioning broad adult populations with Relapsing Remitting Multiple Sclerosis (RRMS). Thus, specific considerations such as age or gender-related performance were not extensively covered for Ponesimod in comparison to other DMTs.
- Although its efficacy may be lower than some monoclonal antibodies like Natalizumab, based on the studies reviewed, its competitive safety profile along with similar general adverse event rates across high-efficacy DMTs makes it an important consideration in the management of RRMS.
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
Ponvory (ponesimod) Prescribing Information. | 2023 | Janssen Pharmaceuticals, Inc. Titusville, NJ |
Systematic Reviews / Meta-Analyses
Document Title | Year | Source |
---|---|---|
Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis. | 2024 | The Cochrane Database of Systematic Reviews |
Comparative efficacy of therapies for relapsing multiple sclerosis: a systematic review and network meta-analysis. | 2023 | Journal of Comparative Effectiveness Research |
Comparative safety of high-efficacy disease-modifying therapies in relapsing–remitting multiple sclerosis: a systematic review and network meta-analysis. | 2022 | Neurological Sciences |
Efficacy and acceptability of the S1P receptor in the treatment of multiple sclerosis: a meta-analysis. | 2021 | Neurological Sciences |
Clinical Practice Guidelines
Document Title | Year | Source |
---|---|---|
Sphingosine 1-phosphate receptor modulators in multiple sclerosis treatment: a practical review. | 2024 | Annals of Clinical and Translational Neurology |